The Optometrist’s Role in Recognizing and Managing Ocular Toxicities from Targeted Cancer Therapies

Activity Overview

As the number of targeted cancer therapies continues to grow, multidisciplinary care is essential for identifying and managing therapy-related adverse events. In this online, on-demand activity, faculty experts focus on best practices for recognizing and addressing ocular toxicities associated with antibody-drug conjugates, monoclonal antibodies, and selective estrogen receptor degraders to optimize patient outcomes. This educational activity is an archive of the live symposium held on October 1, 2026.

Target Audience

This educational activity is directed toward optometrists, ophthalmologists, oncologists, and other eye care professionals involved in the care of patients experiencing ocular toxicities secondary to targeted cancer therapies.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Explain the mechanistic drivers of ocular adverse events associated with antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs), and next-generation targeted cancer therapies across tumor types
• Apply evidence-based prophylactic, monitoring, and management strategies for ocular adverse events associated with specific anticancer agents
• Implement eye care assessments into multidisciplinary oncology workflows by utilizing structured reporting, standardized terminology, and proactive communication
• Construct shared decision-making strategies that engage patients in ocular toxicity prevention, symptom reporting, and risk–benefit discussions

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

PER^® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This accredited continuing education activity was planned in accordance with the ACCME Standards for Integrity and Independence to ensure balance, objectivity, independence, and scientific rigor. Faculty were instructed to use generic names when possible and to base recommendations on the best available evidence. Proprietary product names may be referenced in clinical discussion for educational purposes only and do not imply endorsement.

This activity may include discussion of investigational, unapproved, or off‑label uses of drugs or devices. Learners are advised to consult prescribing information for products discussed. Content is provided for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Learners are encouraged to critically evaluate the information presented and apply their own clinical judgment.

The views expressed are those of the individual faculty members and do not necessarily reflect the views of the accredited provider or any entity providing commercial support.

This activity may have used AI-assisted tools to support educational development. All content was reviewed and approved by qualified faculty or planners. The accredited provider retains full responsibility for accuracy, balance, and independence.